The 2 most recent market catalysts affecting $RTN, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Nov 18, 2026
Corporate Catalyst
Neutral
Impact 75
Retension Pharmaceuticals Reports Third Quarter 2026 Financial Results and Corporate Update
Retension Pharmaceuticals reported its Q3 2026 results, which included the significant news of completing an upsized IPO in October 2026, generating $51.75 million. This capital in…
Oct 9, 2026
Corporate Catalyst
Neutral
Impact 75
Reported Earlier, Retension Pharmaceuticals Prices Upsized Initial Public Offering Of 3.75M Shares At $12.00 Each For $45.0M Gross Proceeds To Fund RTN-001 Phase 2b And Phase 3 Hypertension Trials
This headline is a significant positive catalyst for Retension Pharmaceuticals (RTN) as it secures crucial funding for its lead drug candidate, RTN-001. The successful upsizing of …
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.